89Bio Inc (ETNB)

$ 23.99
-0.94 (-3.77%)
-
Symbol ETNB
Price $ 23.99
Beta 0.000
Volume Avg. 0.10M
Market Cap 0.48B
Shares () -
52 Week Range 18.014-42.36
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -34.94% Strong Sell
ROA -23.45% Sell
Operating Margin -
Debt / Equity 4.00% Neutral
P/E -
P/B 2 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

- Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 - ...

GlobeNewsWire
89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 Conference

89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 Conference

New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients with NASH New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients with NASH ...

GlobeNewsWire
89bio to Present at the Oppenheimer 31st Annual Healthcare Conference

89bio to Present at the Oppenheimer 31st Annual Healthcare Conference

SAN FRANCISCO, March 11, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases... ...

GlobeNewsWire
89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference

89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference

SAN FRANCISCO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases,... ...

GlobeNewsWire
89bio: NASH Drug Developer With Differentiated Profile

89bio: NASH Drug Developer With Differentiated Profile

BIO89-100 is lead and only molecule targeting NASH with superior early-stage data. Among its peer group, molecule is well differentiated. ...

Seeking Alpha
89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference

89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference

SAN FRANCISCO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases,... ...

GlobeNewsWire
89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD's The Liver Meeting® 2020

89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD's...

– Data demonstrated compelling efficacy profile and favorable tolerability with weekly and every two-week dosing – ...

GlobeNewsWire
89bio Reports Third Quarter 2020 Financial Results and Provides Corporate Update

89bio Reports Third Quarter 2020 Financial Results and Provides Corporate Update

– Updated clinical data from BIO89-100 's Phase 1b/2a NASH trial to be presented as a late-breaking poster at upcoming AASLD Liver Meeting – ...

GlobeNewsWire
IPO Update: Metacrine Seeks $85 Million U.S. IPO

IPO Update: Metacrine Seeks $85 Million U.S. IPO

Metacrine has filed to raise $85 million in an IPO of its common stock. The firm is developing treatments for NASH, a liver disease whose prevalence is increasing rapidly. ...

seekingalpha.com
89bio (ETNB) Investor Presentation - Slideshow

89bio (ETNB) Investor Presentation - Slideshow

The following slide deck was published by 89bio, Inc. in conjunction with this event.. ...

seekingalpha.com

About


Mr. Rohan Palekar
Healthcare
Biotechnology
Nasdaq Global Market

89bio, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 17 full-time employees. The firm is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH). FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism.